Cancer is a type of chronic disease in which cell in the body witness abnormal and uncontrolled growth, resulting in the formation of a mass known as tumor, which is cancerous or benign in nature. Head and neck cancer is referred for various malignant tumors developed around nose, throat, larynx, sinuses, and mouth. Furthermore, this type of cancer can develop in squamous cells, which line moist surfaces such as mouth, nose, and throat. Furthermore, salivary glands contain different types of cells that can turn cancerous. The primary risk factors for head and neck cancer are excessive alcohol consumption, chewing tobacco, infection with human papillomavirus (HPV), etc. Other risk factors include excessive consumption of paan (betel quid), preserved or salted foods, oral health, occupational exposure, radiation exposure, Epstein barr virus infection, and due to hereditary causes.
Increasing cases of head and neck cancer is expected to drive growth of the global head and neck cancer market during the forecast period. According to National Center for Biotechnology Information, head and neck cancer is the sixth-most common cancer worldwide, with around 630,000 new patients diagnosed every year, in turn resulting in over 350,000 deaths. Symptoms include a change or hoarseness in the voice, a lump or sore that does not heal, sore throat that does not go away, and unexplained and prolonged trouble swallowing. Around 75% of head and neck cancers are associated with tobacco use, including smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers.
Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/530
Growing demand for effective and targeted treatment, in order to enhance survival rates is expected to propel the global head and neck cancer market growth over the forecast period. Head and neck cancer treatment is challenging for oncologists since the choice and affectivity of the treatment differs as per every patient as well as location of the tumor. Since the facial structure is complicated, surgical procedures are considered the preferred mode of treatment. Moreover, post-surgery functions such as talking, chewing, and swallowing are likely to be adversely affected. Physicians opt for surgical therapy in combination with radiation therapy for treatment of the malady. Unfortunately, the survival rate of the head and neck cancer has reduced from 80% to 50% since the present treatment options mainly treat symptoms. However, recent advancements in the field of chemotherapy and radiotherapy allow preserving some of the functions of the face. Moreover, the advent targeted molecular therapy such as monoclonal antibodies, gene therapy, and antibody drug conjugates can provide major growth avenues for growth of the market.
Growing occurrence of head and neck cancer and increasing research activities to develop cost-effective treatment options are the factors which are driving growth of the global head and neck cancer market. According to the World Health Organization, 3 – 5% of the population around the globe suffers from head and neck cancer. Moreover, worldwide around 550,000 new cases of head and neck cancer are diagnosed annually with almost 300,000 deaths annually. While the cancer can affect people across different age groups, it is especially prevalent among people over 50 years of age. Head and neck cancer is projected to result in 13,360 fatalities (3,420 women and 9,940 men) in 2017. These types of cancers are more than twice as common among men as women.
Do You Have Specific Requirement? Ask To Our Experts: https://www.coherentmarketinsights.com/insight/talk-to-analyst/530
Rising elderly population and increasing proactive initiatives by government and non-governmental organizations are expected to create lucrative environment for growth of the global head and neck cancer market.
Key players operating in the head and neck cancer market are AB Science SA, Bayer AG, Bristol-Myers Squibb Company, Acceleron Pharma, Inc., Astellas Pharma Inc., Boston Biomedical, Inc., AbbVie Inc., and AstraZeneca Plc.
In February 2020, Galera Therapeutics, Inc., announced that Avasopasem manganese (GC4419), a novel drug molecule is in their pipeline. Avasopasem manganese (GC4419), the candidate drug molecule is being developed for reducing the severe oral mucositis (SOD) which is normally induced due to radiotherapy. Avasopasem manganese (GC4419) selectively and rapidly convert superoxide into hydrogen peroxide and oxygen, which in turn protect the normal tissues from the ill-effects of superoxide. If the condition is left untreated, the superoxide can attack and damage the non-cancerous tissue, leading to many side-effects, which can limit the efficiency of radiotherapy in the patients.
In February 2020, Nanobiotix, a nanomedicine company announced that the U.S. Food and Drug Administration (U.S. FDA) granted fast track designation for the radioenhancer NBTXR3, in the presence or absence of Cetuximab for the treatment of patients suffering from locally advanced head and neck squamous cell cancer and are not eligible for platinum-based chemotherapy. During the phase I/II of the clinical trials, the patients suffering from head and neck cancer, showed complete or partial response to the treatment. Therefore, the company plans to initiate phase III of the clinical trials in order to further assess the treatment of NBTXR3 for the head and neck cancer.
In January, 2020, The John Hopkins University announced that they planned to launch treatment de-escalation trial i.e., for patients suffering from HPV related head and neck cancer and responding to the low intensity of treatments, such patients would be subjected for immunotherapy treatment followed by surgery. While the patients suffering from traditional head and neck cancers would be treated with half doses of chemotherapy and radiotherapy. After this treatment, if the remaining of HPV observed in the saliva and blood of these treated patients, then they will be treated with immunotherapy, in order to eliminate the chance of relapse.
On June, 2019, Merck & Co., Inc., announced the U.S. Food and Drug Administration (U.S. FDA) approval for pembrolizumab for the first-line treatment of patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC).
In March 2019, The International Agency for Research on Cancer (IARC) launched a website, Translational Studies of Head and Neck Cancer in South America and Europe (HEADSpAcE). The data published on the website includes the reasons which lead to poor prognosis of head and neck cancers, especially in Europe and South America. Reasons for late diagnosis; influence of lifestyle, types of infections, and genetic factors on poor outcome etc.
In October 2018, Sanofi S.A. received the U.S. FDA approval for the Taxotere, a supplemental new drug which is in the form of injection concentrate. It is injected in combination with cisplatin and fluorouracil for the treatment of patient’s suffering from inoperable locally advanced head and neck squamous cell carcinoma.
In 2016, Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (U.S. FDA) approval for nivolumab (OPDIVO Injection,), which has been indicated for the treatment of patients suffering from advanced stage of head and neck squamous cell carcinoma (HNSCC) after undergoing platinum-containing chemotherapy.
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/530
Head and Neck Cancer Market Taxonomy
By Disease Indication
Laryngeal and Hypo pharyngeal Cancer
Nasal Cavity and Paranasal Sinus Cancer
Oral and Oropharyngeal Cancer
Salivary Gland Cancer
By Drug Class
Reasons to Purchase this Report
• Current and future of global Head and Neck Cancer Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/530
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Head and Neck Cancer Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Head and Neck Cancer Industry Impact
Chapter 2 Global Head and Neck Cancer Competition by Types, Applications, and Top Regions and Countries
2.1 Global Head and Neck Cancer (Volume and Value) by Type
2.3 Global Head and Neck Cancer (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Head and Neck Cancer Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Head and Neck Cancer Market Analysis
Chapter 6 East Asia Head and Neck Cancer Market Analysis
Chapter 7 Europe Head and Neck Cancer Market Analysis
Chapter 8 South Asia Head and Neck Cancer Market Analysis
Chapter 9 Southeast Asia Head and Neck Cancer Market Analysis
Chapter 10 Middle East Head and Neck Cancer Market Analysis
Chapter 11 Africa Head and Neck Cancer Market Analysis
Chapter 12 Oceania Head and Neck Cancer Market Analysis
Chapter 13 South America Head and Neck Cancer Market Analysis
Chapter 14 Company Profiles and Key Figures in Head and Neck Cancer Business
Chapter 15 Global Head and Neck Cancer Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027